TY - JOUR
T1 - Treatment of buccal mucosal carcinomas
T2 - A survey amongst head and neck surgeons in the Netherlands
AU - Adriaansens, Carleen M.E.M.
AU - Noorlag, Rob
AU - de Bree, Remco
AU - van Es, Robert J.J.
N1 - Funding Information:
This work was supported by KWF, the Dutch Cancer Society, grant number: 13577.
Funding Information:
We would like to thank Johannes Rijken, head and neck surgeon at UMC Utrecht and Reinoud Klijn, head and neck surgeon at Medical Spectrum Twente for piloting and improving the questionnaire. We would also like to thank all the head and neck surgeons in the Netherlands who participated in this research by replying to the questionnaire.
Publisher Copyright:
© 2023 The Authors. Laryngoscope Investigative Otolaryngology published by Wiley Periodicals LLC on behalf of The Triological Society.
PY - 2023/8
Y1 - 2023/8
N2 - Objective: Currently, there is no up-to-date guideline for the treatment of buccal mucosal squamous cell carcinoma (BMSCC) in the Netherlands. A questionnaire was used to investigate the opinions of Dutch head and neck surgeons on BMSCC of the cheek treatment. Methods: A questionnaire was sent to all 91 head and neck surgeons in the Netherlands. Their opinions on surgical tumor-free margins, through-and-through defects, and indications for local adjuvant therapy were questioned. Results: The response rate was 51%. To prevent a through-and-through defect, 67% of the surgeons would accept a deep clinical (macroscopic) margin of ≤5 mm. The less adverse histological characteristics a tumor has, the less consensus there is amongst the surgeons for local adjuvant treatment in case of close margins. Conclusion: There is no consensus amongst Dutch head and neck surgeons about the optimal treatment for BMSCC of the cheek. There are different opinions on acceptable resection margins, indications for a through-and-through defect, and indications for adjuvant treatment. BMSCC of the cheek treatment should be more uniform and less surgeon dependent. Level of evidence: N/A.
AB - Objective: Currently, there is no up-to-date guideline for the treatment of buccal mucosal squamous cell carcinoma (BMSCC) in the Netherlands. A questionnaire was used to investigate the opinions of Dutch head and neck surgeons on BMSCC of the cheek treatment. Methods: A questionnaire was sent to all 91 head and neck surgeons in the Netherlands. Their opinions on surgical tumor-free margins, through-and-through defects, and indications for local adjuvant therapy were questioned. Results: The response rate was 51%. To prevent a through-and-through defect, 67% of the surgeons would accept a deep clinical (macroscopic) margin of ≤5 mm. The less adverse histological characteristics a tumor has, the less consensus there is amongst the surgeons for local adjuvant treatment in case of close margins. Conclusion: There is no consensus amongst Dutch head and neck surgeons about the optimal treatment for BMSCC of the cheek. There are different opinions on acceptable resection margins, indications for a through-and-through defect, and indications for adjuvant treatment. BMSCC of the cheek treatment should be more uniform and less surgeon dependent. Level of evidence: N/A.
KW - buccal mucosal squamous cell carcinoma
KW - head and neck surgeon
KW - questionnaire
KW - through-and-through defect
KW - ultrasound
UR - http://www.scopus.com/inward/record.url?scp=85161441480&partnerID=8YFLogxK
U2 - 10.1002/lio2.1081
DO - 10.1002/lio2.1081
M3 - Article
C2 - 37621291
AN - SCOPUS:85161441480
SN - 2378-8038
VL - 8
SP - 857
EP - 864
JO - LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY
JF - LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY
IS - 4
ER -